



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

CERTIFIED COPY OF PRIORITY DOCUMENT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 10 February 2005

BEST AVAILABLE COPY

THIS PAGE BLANK (USPTO)

F25

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form))

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

P.72841 TAC

2. Patent application number

(The Patent Office will fill in this part)

25 APR 1997

9708526.0


3. Full name, address and postcode of the or of each applicant (underline all surnames)

Royal Free Hospital School of Medicine
Rowland Hill Street, London, NW3 2PF
UNITED KINGDOM

Patents ADP number (if you know it)

UNITED KINGDOM

If the applicant is a corporate body, give the country/state of its incorporation



4. Title of the invention

EUKARYOTIC GENE EXPRESSION CASSETTE AND USES THEREOF

5. Name of your agent (if you have one)

J A KEMP & CO

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

14 SOUTH SQUARE
GRAY'S INN
LONDON WC1R 5LX

Patents ADP number (if you know it)

26001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer "Yes" if:

☒ YES

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body:
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	15
Claim(s)	4 ³
Abstract	1
Drawing(s)	5 ³

10. If you are also filing any of the following, state how many against each item.

Priority documents
Translations of priority documents
Statement of inventorship and right to grant of a patent (Patents Form 7/77)
Request for preliminary examination and search (Patents Form 9/77)
Request for substantive examination (Patents Form 10/77)
Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application
Signature J. A. Kemp & Co Date 25 April 1997
12. Name and daytime telephone number of person to contact in the United Kingdom CRESSWELL, THOMAS ANTHONY
0171 405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered "Yes" Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

EUKARYOTIC GENE EXPRESSION CASSETTE AND USES THEREOF

The present invention relates to a gene expression cassette. The expression cassette can be used for directing expression of heterologous genes in eukaryotic cells. It also relates to the use of said expression cassette in gene therapy and vaccine production. It further relates to vectors, including viral strains, comprising said expression cassette.

Background to the invention

Anderson-Fabry disease is a lysosomal storage disorder (LSD) resulting from the deficiency of the lysosomal enzyme alpha-galactosidase (alpha-gal, EC 3.2.1.22). This enzymatic defect leads to the deposition of neutral glycosphingolipids in most tissues, the pathological and clinical manifestations of the disease being the result of progressive accumulation in endothelial cells leading to ischemia and infarction in organs like kidney, heart or brain.

In addition to the sorting mechanisms operating in the trans-Golgi network, lysosomal enzymes can also be recaptured from the extracellular space via mannose-6-phosphate receptors. In keeping with this, it has been shown that the administration of purified lysosomal enzymes to the culture medium can correct the enzymatic defect in fibroblasts from patients with various types of LSD. This ability of cells to take up the enzyme has provided the basis for the use of replacement therapy for this group of disorders. In the case of Fabry disease, early studies showed that alpha-gal partially purified from various sources is taken-up by skin fibroblasts from Fabry hemizygotes when added to the culture medium and does catabolize the accumulated substrate, globotriaosylceramide (CTH). This prompted several clinical trials of enzyme replacement in the 1970s which demonstrated the feasibility of enzyme therapy for Fabry disease. However, the unavailability of sufficient amounts of the purified human enzyme has prevented a proper evaluation of the efficacy of replacement therapy so far.

Alternative ways of providing a source of active enzyme for the treatment of LSD have included bone marrow transplantation and, more recently, gene transfer into haematopoietic stem cells or enzyme delivery into the whole organism by genetically modified cells. For instance, it has been recently shown that fibroblasts transfected with

retroviral vectors and grown on collagen lattices which were implanted in the peritoneal cavity successfully secreted beta-glucuronidase and corrected the storage lesions in the liver and spleen of Mucopolysaccharidosis VII mice. The same approach resulted in long-term secretion of this enzyme in dogs and similar results were obtained in nude mice
5 transplanted with neo-organs which were secreting alpha-L-iduronidase.

Since the discovery that skeletal muscle can be transfected *in vivo* by intramuscular injection of plasmid DNA, this organ system has attracted considerable attention as a potential source of secreted therapeutic proteins. Injection of plasmid DNA constructs has been used successfully for the expression of dystrophin, factor VII,
10 apolipoprotein-E and alpha-1 antitrypsin, whereas intramuscular injection of genetically modified myoblasts gave encouraging results in the secretion of human growth hormone, factor IX, beta-glucuronidase, human and murine erythropoietin and human glucocerebrosidase. However, the efficiency of these methods of transfection is still low, even with the induction of muscle degeneration and regeneration through injection of
15 myotoxic substances prior to the injection of DNA. Direct plasmid injection in muscle shows better transfection efficiency than viral vectors and plasmid DNA has been found to be maintained extrachromosomally for at least 19 months. Moreover, the safety, simplicity and low-cost of intramuscular injection of plasmid DNA make it a very attractive alternative to other methods. However, most studies so far have shown that
20 expression is not high enough to increase the blood levels of circulating proteins.

Summary of the Invention

The present invention relates to an expression cassette comprising, operably linked, (i) a myosin light chain enhancer, (ii) a promoter selected from a myosin heavy
25 chain promoter and a viral promoter and (iii) a polynucleotide sequence of interest.

Nucleic acid constructs, including virus strains, comprising said expression cassette can be used, for example, for delivering therapeutic genes in methods of treatment of diseases, for example Fabry disease, or for the delivery of genes encoding specific antigens for vaccine purposes.

Accordingly the present invention provides an expression cassette comprising, operably linked, (i) a myosin light chain enhancer, (ii) a promoter selected from a myosin heavy chain promoter and a viral promoter and (iii) a polynucleotide sequence of interest.

Preferably, the enhancer is a myosin light chain 1/3 enhancer. Preferably the myosin heavy chain promoter is a mammalian heavy chain promoter, more preferably a truncated rabbit β -myosin heavy chain promoter. Preferably the viral promoter is a cytomegalovirus (CMV) or herpes simplex virus (HSV) promoter.

The expression cassette of the invention may thus be used to deliver a polynucleotide sequence of interest to a eukaryotic cell where it will be expressed. Vectors and viral strains comprising the expression cassette of the invention may also be used to deliver a polynucleotide sequence of interest to a eukaryotic cell where it will be expressed. Preferably the cell is a vertebrate cell, more preferably an avian, fish or mammalian muscle cell. Such expression cassettes, vectors and viral strains are useful in a variety of applications, for example, in methods of medical treatment including gene therapy and as vaccines.

Preferably, the polynucleotide sequence of interest comprises a heterologous gene. The heterologous gene may be any allelic variant of a wild-type gene, or it may be a mutant gene. The heterologous gene preferably encodes a polypeptide of therapeutic use.

The invention further provides for the use of the expression cassette, vectors and viral strains, comprising the expression cassette, for use in the treatment of humans and animals.

The invention also provides a method for producing a viral strain comprising an expression cassette of the invention, which method comprises introducing an expression cassette of the invention into the genome of the virus strain, preferably by homologous recombination.

Detailed Description of the Invention

A. **Expression Cassette** - myosin light chain enhancer, myosin heavy chain promoter/viral promoter, polynucleotide sequences of interest

The expression cassette of the invention comprises, operably linked, (i) a myosin light chain enhancer, (ii) a promoter selected from a myosin heavy chain promoter and a viral promoter and (iii) a polynucleotide sequence of interest. The term "operably linked" refers to a juxtaposition wherein the components are in a relationship permitting them to function in their intended manner. Thus, for example, a promoter operably linked to a polynucleotide sequence of interest is ligated in such a way that expression of the polynucleotide sequence of interest is achieved under conditions which are compatible with the activation of expression from the promoter.

The expression cassette can be constructed using routine cloning techniques known to persons skilled in the art (see, for example, Sambrook *et al.*, 1989, Molecular Cloning - a laboratory manual; Cold Spring Harbor Press).

2. Myosin enhancer

Several myosin enhancers have been identified to date from both myosin light chain and myosin heavy chain genes. Preferably the enhancer used in the expression cassette of the present invention is of vertebrate origin, more preferably avian, piscine or mammalian origin. A myosin light chain enhancer is preferred. A rat myosin light chain 1/3 enhancer (Donoghue *et al.*, 1988; Neville *et al.*, 1996), is especially preferred. The enhancer is operably linked to the promoter. The term 'operably linked' is as defined above. The enhancer may be either upstream or downstream of the promoter. The enhancer may be used in either orientation.

3. Promoters

The promoter in the expression cassette of the invention is selected from myosin heavy chain promoters or viral promoters which are functional in vertebrate cells, preferably avian, piscine and/or mammalian, preferably human, cells. The myosin heavy chain promoter is preferably a truncated rabbit β -cardiac myosin heavy chain promoter, in particular up to and including 789 base pairs upstream of the transcription start site. Another myosin heavy chain promoter which is especially preferred is the carp FG2 promoter, in particular up to and including 901 base pairs upstream of the transcription start site (Gauvry *et al.*, 1996). Further details of myosin heavy chain promoters derived

from rat, rabbit, human, porcine and chick myosin heavy chain genes are given in Gauvry *et al.*, 1996 and references therein. Viral promoters include CMV and HSV promoters. CMV IE promoters are especially preferred.

5 4. Polynucleotide sequences of interest

 The term "polynucleotide sequence of interest" is intended to cover nucleic acid sequences which are capable of being at least transcribed. The sequences may be in the sense or antisense orientation with respect to the promoter. Antisense constructs can be used to inhibit the expression of a gene in a cell according to well-known techniques. The polynucleotide sequence of interest may comprise a heterologous gene. The term heterologous gene encompasses any gene. Thus sequences encoding mRNA, tRNA and rRNA are included within this definition. The heterologous gene may be any allelic variant of a wild-type gene, or it may be a mutant gene. Sequences encoding mRNA will optionally include some or all of 5' and/or 3' transcribed but untranslated flanking sequences naturally, or otherwise, associated with the translated coding sequence. The polynucleotide sequence of interest may optionally further include the associated transcriptional control sequences normally associated with the transcribed sequences, for example transcriptional stop signals, polyadenylation sites and downstream enhancer elements.

20 The polynucleotide sequence of interest preferably encodes a therapeutic product, which can for example be a peptide, polypeptide, protein or ribonucleic acid. More especially, the coding sequence is a DNA sequence (such as cDNA or genomic DNA) coding for a polypeptide product such as enzymes (e.g. α -galactosidase), blood derivatives, hormones, cytokines, namely interleukins, interferons or TNF, growth factors (e.g. IGF-1), neurotransmitters or their precursors or synthetic enzymes, trophic factors such as BDNF, CNTF, NGF, IGF, GMF, aFGF, bFGF, NT3 and NT5; apolipoproteins, such as ApoAI, ApoAIV and, dystrophin or a minidystrophin, tumour-suppressing genes such as p53, Rb, Rap1A, DCC and k-rev, genes coding for factors involved in coagulation such as factors VII, VIII and IX or alternatively all or part of a natural or artificial immunoglobulin (e.g. Fab and ScFv).

The coding sequence can also be an antisense sequence, whose expression in the target cell enables gene expression or the transcription of cellular mRNAs to be controlled. Such sequences can, for example, be transcribed in the target cell into RNAs complementary to cellular mRNAs and can thus block their translation into protein, according to the technique described in European Patent No. 140,308. In particular, antisense sequences can be used to block translation of inflammatory or catabolic cytokines in the treatment of arthritis and tissue loss caused by these cytokines.

The present invention may also be used for the expression of sequences coding for toxic factors. The latter can be, in particular, cell poisons (such as diphtheria toxin, pseudomonas toxin and ricin A), a product inducing sensitivity to an external agent (suicide genes: e.g. thymidine kinase and cytosine deaminase) or alternatively killer genes capable of inducing cell death (e.g. Grb3-3 and anti-ras ScFv).

Preferably, the polynucleotide sequence of interest encodes a polypeptide of therapeutic use. For example, of the proteins described above, α -galactosidase can be used to treat Fabry disease.

Polynucleotide sequences of interest may also encode antigenic polypeptides or nucleic acids for use as vaccines. Preferably such antigenic polypeptides or nucleic acids are derived from pathogenic organisms, for example bacteria or viruses. For example, antigenic polypeptides or nucleic acids may be selected from regions of the hepatitis C virus genome and gene products. Antigenic determinants present in the genomes or gene products of the causative agents of, for example, viral haemorrhagic septicemia, bacterial kidney disease, vibriosis and furunculosis are particularly preferred.

Heterologous genes may also include marker genes (for example encoding β -galactosidase or green fluorescent protein) or genes whose products regulate the expression of other genes.

B. Vectors

The expression cassette may be used in the form of a naked nucleic acid construct. Alternatively, it may be introduced into a variety of nucleic acid vectors. Such vectors

include plasmids and viral vectors. Vectors may further include sequences flanking the expression cassette which comprise sequences homologous to eukaryotic genomic sequences, preferably mammalian genomic sequences, or viral genomic sequences. This will allow the introduction of the expression cassette into the genome of eukaryotic cells or viruses by homologous recombination. In particular, a plasmid vector comprising the expression cassette flanked by viral sequences can be used to prepare a viral vector suitable for delivering the expression cassette to a vertebrate, including fish, avian or mammalian, cell. The techniques employed are well-known to a skilled person.

D. Administration

The expression cassette of the invention may thus be used to deliver therapeutic genes to a human or animal in need of treatment. Alternatively, the expression cassette of the invention may be used to deliver genes encoding potentially immunogenic polypeptides *in vivo* for vaccine purposes particularly the vaccination of fish.

The expression cassette of the invention may be administered directly as a naked nucleic acid construct, preferably further comprising flanking sequences homologous to the host cell genome. Uptake of naked nucleic acid constructs by vertebrate cells is enhanced by several known techniques including biolistic transformation and lipofection.

Alternatively, the expression cassette may be administered as part of a nucleic acid vector, including a plasmid vector or viral vector.

Preferably the delivery vehicle (i.e. naked nucleic acid construct or viral vector comprising the expression cassette for example) is combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition is typically formulated for intramuscular administration.

Preferably, the substance is used in an injectable form. It may therefore be mixed with any vehicle which is pharmaceutically acceptable for an injectable formulation, preferably for a direct injection at the site to be treated. The pharmaceutically carrier or diluent may be, for example, sterile or isotonic solutions. It is also preferred to formulate that substance in an orally active form. Methods for injecting nucleic acids into fish

muscle are described in Gauvry *et al.*, 1996.

The actual formulation used can be readily determined by the skilled person and will vary depending on the nature of the substance to be administered and the route of administration

5 The dose of substance used may be adjusted according to various parameters, especially according to the substance used, the age, weight and condition of the patient to be treated, the mode of administration used and the required clinical regimen. A physician will be able to determine the required route of administration and dosage for any particular patient and condition.

10 The invention will be described with reference to the following Example which are intended to be illustrative only and not limiting.

EXAMPLE

Brief description of the figures

15 Figure 1 and Figure 2 are graphs showing a comparison of alpha-gal and beta-gal activity obtained using three different constructs.

20 Figure 3 is a graph showing alpha-gal activity in the cell extracts/supernatants obtained from myoblasts transfected with three different constructs.

25 Figure 4 is a graph showing alpha-gal activity in cell extracts from fibroblasts from a Fabry patient which have been transfected with an alpha-gal expressing construct.

 Figure 5 is a graph showing alpha-gal activity in muscle extracts 7 days after injection with an alpha-gal expressing construct.

Detailed description of the figures

Figure 1:

- 5 **A.** Comparison of constructs pIVGF, pX4F and pMCagalF after transfection of C2C12 myoblasts (see Table 1 for details of constructs). DNA for transfections was prepared using Plasmid midi-columns (Qiagen, Dorking, UK). C2C12 mouse myoblasts were plated at 1.5×10^4 cells/cm² and grown overnight in growth medium (DMEM/10%FCS with penicillin-streptomycin-amphotericin B). Transfections were performed mixing 10
- 10 μ g of Lipofectamine (Gibco, Paisley, UK) with 2 μ g of DNA in 200 μ l of Optimem-1 (Gibco, Paisley, UK). After 30 min incubation at room temperature, the mixture was diluted up to 1 ml in Optimem-1 and added to the cells. Transfections were carried out for 6-8 hours at 37°C/5% CO₂ and included pCMV-b (typically 200 ng in 2 μ g of total DNA) which drives the expression of beta-galactosidase. The latter was used as an internal
- 15 control of transfection efficiency. After transfection, plates were washed with PBS followed by addition of DMEM/2% horse serum (differentiation medium). Under these conditions, myoblasts start the process of fusion and differentiation into myotubes, which become visible after 48 hours and continue to develop for 4-6 days. Enzymatic activities of alpha-galactosidase and beta-galactosidase in cell extracts were assayed
- 20 fluorimetrically with specific substrates, so that both reactions do not show any cross-reactivity. Normalized alpha-gal enzymatic activity (in Units alpha-gal/Unit beta-gal) is shown 18 hours post-transfection (undifferentiated myoblasts). High-Low bars show the results from duplicate experiments.
- 25 **B.** Comparison of constructs pIVGF, pX4F and pMCagalF after transfection of C2C12 myoblasts as indicated above. Normalized alpha-gal enzymatic activity (in Units alpha-gal/Unit beta-gal) is shown 10 days post-transfection (fully differentiated myotubes). Note that the values reflect not only the change in alpha-gal but also the decrease in beta-gal (the reporter enzyme used to correct for transfection efficiency), which is driven by
- 30 the CMV promoter alone. Therefore, the actual normalized units for each construct cannot be compared directly with the values obtained from undifferentiated myoblasts (shown in

Fig. 1A). However, since all constructs are co-transfected with exactly the same amount of the same internal control plasmid, a direct comparison can be made between constructs at a given time point post-transfection. High-Low bars show the results from duplicate experiments.

Figure 2: Comparison of constructs pX3F and pX4F after transfection of C2C12 myoblasts as indicated in Fig. 1. Normalized alpha-gal enzymatic activity (in Units alpha-gal/Unit beta-gal) is shown 6 days post-transfection (fully differentiated myotubes). High-Low bars show the results from duplicate experiments.

Figure 3: Total alpha-gal activity (in Units, 1 Unit= 1 nmol/h) of cell extracts and of supernatants from C2C12 myoblasts transfected with three different constructs (Mock - no DNA transfected) and harvested 48 hours after transfection. Total alpha-gal activity was derived from the original enzymatic activity in cell extracts (in Units/mg) or in supernatants (in Units/L). High-low bars show the results from duplicate experiments.

Figure 4: Alpha-gal activity in cell extracts from fibroblasts of a Fabry patient that were cultured for 4 days in medium conditioned by C2C12 myoblasts transfected as indicated, either in the absence or in the presence (+M6P) of 5mM mannose-6-phosphate (Sigma, Poole, UK) in the culture medium. Conditioned media were 0.22mm-filtered before being added to the fibroblasts in order to avoid carry-over of the liposome-DNA complex. Proteins were measured using the bicinchonic acid method (Sigma, Poole, UK).

Error bars=S.E.M. (n=6).

*Significant difference ($p<0.01$) with any of the other groups (Mann-Whitney ranks-sum test for unpaired samples).

Figure 5: Alpha-gal activity (in Units/mg of protein) in *tibialis anterior* muscle extracts 7 days after injection. DNA of construct pX7F was prepared using the Endo-free Plasmid Kit (Qiagen, Dorking, UK). 30 mg of DNA in 50 ml of sterile, endotoxin-free saline (or 50 ml of saline in control muscles) were injected in tibialis anterior muscles of 5-6 week-old C57Bl/6 mice following previous recommendations³¹. Mice were anaesthetized with Hypnorm-Diazepam and the DNA solution was injected percutaneously in the centre of

the muscle with a tuberculin syringe fitted with a 27G needle, using a perpendicular approach.

Seven days after injection the animals were sacrificed and the muscles were dissected and frozen at -70°C , finely ground on a pre-cooled mortar and then vortexed for 15 min at room temperature in 500 ml of Reporter Lysis Buffer (Promega, Southampton, UK), spun for 3 min. at 4°C and the supernatants stored at -70°C . Proteins and alpha-gal enzymatic activity were determined as described above, and results were expressed in Units/mg of protein.

Error bars=S.E.M. (n=6).

p<0.01 (Mann-Whitney ranks-sum test for unpaired samples).

Effect of muscle-specific regulatory elements

We have made several vectors driving the expression of human alpha-gal and we have compared them following transfection of the myogenic cell line C2C12. This cell line has been extensively used as a model of muscle differentiation in the study of muscle-specific regulatory elements, due to the ability of these myoblasts to undergo fusion and differentiation under certain culture conditions. Once mature myotubes are formed, they cannot be transfected by non-viral methods. Therefore, the standard transfection protocol starts with transfection of undifferentiated myoblasts with cationic liposomes followed by differentiation to mature myotubes. Gene expression can be measured at any time point during the differentiation process, so that this system also allows a comparison of the activity of regulatory elements before and after the activation of muscle-specific genes. However, transfection efficiency must be carefully controlled by co-transfection with a different plasmid driving the expression of a reporter gene. This is used as an internal control which corrects for the differences between constructs and between plates.

We first compared three constructs containing a muscle-specific promoter (rabbit myosin heavy chain) or the human cytomegalovirus promoter combined with the myosin light chain 1/3 enhancer (see Table I for details of the constructs). The MLC1/3 enhancer has been shown to result in muscle-specific expression of heterologous genes in transgenic mice and zebrafish.

The construct in which alpha-gal expression is driven by the CMV promoter alone (pIVGF) showed the highest activity in undifferentiated myoblasts (18 hours post-transfection), followed by pX4F and pMCagalF in this order (Fig. 1A). In contrast, the analysis of fully differentiated myotubes (10 days post-transfection) revealed that alpha-gal enzymatic activity was clearly higher in pX4F than in pIVGF (Fig. 1B), the only difference between both constructs being the presence of the MLC1/3 enhancer in pX4F. Our results show that this enhancer element can increase the strength of the expression driven by the CMV promoter in differentiated myogenic cells, but exerts little or no enhancing effect in undifferentiated myoblasts. We have also compared the expression levels generated by pX3F and pX4F, which only differ in the orientation of the MLC1/3 enhancer. Both constructs showed the same activity after 6 days in differentiation medium (Fig. 2), confirming that the orientation of the enhancer does not affect the levels of expression. This supports previous data showing that this enhancer increases the activity of the SV40 promoter in mature myotubes in an orientation-independent manner and suggests that muscle differentiation provides the necessary muscle-specific factors which enable this element to enhance the basal activity of heterologous promoters.

CONSTRUCT	PARENT VECTOR	PROMOTER	ENHANCER
pMCagalF	pbPASE9	MHC	MLC1/3
pIVGF	pcDNA3	CMV	---
pX3F	pcDNA3	CMV	MLC1/3 (sense)
pX4F	pcDNA3	CMV	MLC1/3 (antisense)
pX7F	pcDNA3	CMV	MLC1/3 (sense)

*pcDNA3 (Invitrogen, DeSchelp, The Netherlands)

Table 1: Details of the expression vectors used in this study. Rabbit β -cardiac myosin heavy chain (MHC) promoter consists of 781 bases of the promoter region. Myosin light chain 1/3 enhancer (MLC1/3) has accession number X14726. CMV is the major intermediate early promoter/enhancer region of human cytomegalovirus. Constructs pX3F, pX4F and pX7F contain the MLC1/3 enhancer cloned either in the direction of transcription (sense) or in the reverse orientation (antisense) as indicated. For the

generation of pX3F, pX4F and pIVGF, the cDNA coding for alpha-galactosidase was amplified by RT-PCR and cloned in pCRIITM (Invitrogen, DeSchelp, The Netherlands), resulting in pGal-wt. EcoRI digestion of pGal-wt releases the alpha-gal cDNA without flanking sequences which was used in the appropriate vectors. For the construction of pX7F we used a different fragment containing the cDNA for alpha-gal (gift from Dr. H. Sakuraba) which only contains 25 bp of 5'-UTR and no flanking sequences. Thus, pX3F and pX7F differ only in the length of the 5'-UTR of alpha-gal (35 bp longer in pX3F).

Secretion of human alpha-gal to the culture medium and uptake by alpha-gal-deficient fibroblasts

In a different set of experiments, we have assayed the total activity of alpha-gal in cell extracts and in supernatants conditioned for 48 hours after transfection with constructs pX3F, pX4F or pX7F, relative to controls (mock transfected, no DNA). The total amount of alpha-gal activity in the culture medium of transfected cells was significantly higher than in controls (average of the three constructs =2.17 Units vs. 0.10 Units in controls, results not shown). In order to confirm that the alpha-gal expressed and secreted *in vitro* has undergone correct post-translational processing, we investigated the ability of alpha-gal-deficient fibroblasts to take up the enzyme from medium conditioned by C2C12 myoblasts transfected with pX7F. Fibroblasts from a hemizygous Fabry patient (which show low enzymatic activity) were cultured for 4 days in differentiation medium that had been conditioned by C2C12 myoblasts transfected with pX7F. Fig. 3 shows the alpha-gal enzymatic activity in fibroblasts kept under these conditions; significantly higher levels were detected in those cultured with medium conditioned by pX7F-transfected myoblasts than in those cultured with medium conditioned by mock-transfected myoblasts ($p<0.01$). This effect was completely abolished by the addition of mannose-6-phosphate (5 mM) to the conditioned medium (Fig. 3), showing that this increase in alpha-gal activity was the result of uptake of the enzyme via mannose-6-phosphate receptors. This strongly suggests that the enzyme contained appropriate post-translational modifications, like phosphomannosyl residues. To our knowledge, this is the first report in which a correctly glycosylated form of human alpha-gal was expressed and secreted from differentiated muscle cells.

Production of human alpha-gal after intramuscular injection of plasmid DNA

We have analysed alpha-gal activity in muscle extracts from mice injected intramuscularly with plasmid DNA to see whether we could reproduce these results *in vivo*. This technique does not permit a correction to be made for the number of transfected fibres as can be done *in vitro*. This requires the use of samples of adequate size in order to detect any potential statistical difference. In our experiment (6 muscles in each group), injection of construct pX7F into *tibialis anterior* resulted in significantly increased levels of alpha-gal activity with respect to the control muscles injected with saline ($p < 0.01$) 7 days after injection (Fig. 4). Expression of foreign proteins in muscle has been shown to elicit an immune response against those fibres expressing the protein, which decrease in number and disappear completely two weeks post-injection. For this reason, we have allowed expression to proceed only for one week, analysing enzymatic activity well before the start of the effector phase of the immune response against human alpha-gal. Preliminary results from our laboratory indicate that vectors containing the mouse alpha-gal cDNA can drive the expression of the enzyme for at least four weeks in injected muscles (not shown). The isogenic protein products of therapeutic genes can also trigger an immune response following their delivery in gene therapy. Therefore, measures to prevent or to combat immunogenicity of the targeted protein should be developed. Administration of several different immunomodulating agents, including immunosuppressive drugs and anti-CD4 or anti-CD40L antibodies at the time of gene therapy gave encouraging results. Such a transient ablation of CD4⁺ T cells may prevent the effector phase of immune response to the gene product. Moreover, some Fabry disease patients have missense mutations, possibly with some non-functional protein present. In these cases induction of immune responses to the gene therapy product may be prevented.

Apart from the immune reaction against transfected fibres, other authors have shown that the activity of the CMV-promoter driven expression declines after injection of plasmid constructs with reporter genes. In contrast, vectors containing the RSV promoter showed more sustained expression. The reasons for this difference between promoters is not well understood, but promoter shut-off has been proposed as a mechanism. However,

our results suggest that the MLC1/3 enhancer element can increase and prolong the expression driven by the CMV promoter in conditions that resemble mature muscle fibres. This will have interesting implications for the development of vectors designed for direct plasmid injection in muscle, because it could help to maintain the activity of the CMV promoter for a longer period of time.

In summary, our *in vivo* results show significantly increased production of alpha-gal in muscle after injection of a plasmid expression vector. Together with our data showing that muscle cells can secrete human alpha-gal in its correctly processed form, the results presented here represent a significant step towards the improvement of this expression system and the generation of a strategy for the production of alpha-gal from muscle *in vivo*.

References

- Gauvry L., Ennion S., Hansen, E. Butterworth P. and Goldspink G. (1996) The characterisation of the 5' regulatory region of a temperature-induced myosin heavy chain gene associated with myotomal muscle growth in carp. *Eur. J. Biochem.*, **236**, 887-894
- Donoghue M., Ernst H., Wentworth B., Nadal Ginard G. and Rosenthal N. (1988) A muscle specific enhancer is located at the 3' end of the myosin light chain 1/3 gene locus. *Genes Dev.*, **2**, 1779-1790.
- Neville C., Gonzales D., Houghton, L., McGrew M and Rosenthal N. (1996) Modular elements of the MLC 1f/3f locus confer fiber-specific transcription regulation in transgenic mice. *Dev. Genetics*, **19**, 157-162.
- Rosenthal N., Berglund E., Wentworth B, Donoghue M., Winter B., Braun, Bober E. and Arnold H. (1989) A highly conserved enhancer downstream of the human MLC 1/3 locus is a target for multiple myogenic factors. *Nucleic Acids Res.*, **18**, 6239-6245.

CLAIMS

1. An expression cassette comprising, operably linked, (i) a myosin light chain enhancer, (ii) a promoter selected from a myosin heavy chain promoter and a viral promoter and (iii) a polynucleotide sequence of interest.
2. An expression cassette according to claim 1 wherein said myosin light chain enhancer is a myosin light chain 1/3 enhancer.
3. An expression cassette according to claim 1 or 2 wherein said myosin heavy chain promoter is a fish myosin heavy chain promoter.
4. An expression cassette according to claim 3 wherein said fish myosin heavy chain promoter is a carp FG2 myosin heavy chain promoter.
5. An expression cassette according to claim 1 or 2 wherein said myosin heavy chain promoter is a mammalian myosin heavy chain promoter.
6. An expression cassette according to claim 5 wherein said mammalian myosin heavy chain promoter is a truncated rabbit β -cardiac myosin heavy chain promoter.
7. An expression cassette according to any one of the preceding claims wherein said viral promoter is a cytomegalovirus promoter or a herpes simplex virus promoter.
8. An expression cassette according to any one of the preceding claims wherein said polynucleotide sequence of interest encodes a polypeptide of therapeutic use.
9. An expression cassette according to claim 8 wherein said polypeptide is α -galactosidase.

10. An expression cassette according to any one of the preceding claims for use in delivering said polynucleotide sequence of interest to a eukaryotic cell.
11. An expression cassette according to claim 10 wherein said eukaryotic cell is a muscle cell of a bird, fish or mammal.
12. A nucleic acid vector comprising an expression cassette as defined in any one of the preceding claims.
13. A vector according to claim 12 further comprising avian, fish or mammalian genomic sequences flanking said expression cassette.
14. A vector according to claim 12 or 13 further comprising viral genomic sequences flanking said expression cassette.
15. A viral strain comprising an expression cassette as defined in any one of claims 1 to 11.
16. A method of producing a viral strain according to claim 15 which method comprises introducing an expression cassette as defined in any one of claims 1 to 11 into the genome of a virus.
17. A method of producing a viral strain according to claim 15 which method comprises introducing an expression cassette as defined in any one of claims 1 to 11 into the genome of a virus by homologous recombination between said genome and a vector as defined in claim 14.
18. An expression cassette according to any one of claims 1 to 11, a vector according to any one of claims 12 to 14 or a viral strain according to claim 15 for use in a method of treatment of the human or animal body.

19. An expression cassette according to any one of claims 1 to 11, a vector according to any one of claims 12 to 14 or a viral strain according to claim 15 for use in the treatment of Fabry disease.
20. Use of an expression cassette according any one of claims 1 to 11, a vector according to any one of claims 12 to 14 or a viral strain according to claim 15 in the treatment of Fabry disease.
21. A pharmaceutical composition comprising an expression cassette according to any one of claims 1 to 11, a vector according to any one of claims 12 to 14 or a viral strain according to claim 15 together with a pharmaceutically acceptable carrier or diluent.
22. A method of treatment of the human or animal body which method comprises administering an effective, non-toxic amount of a pharmaceutical composition according to claim 21 to a human or animal in need of such treatment.
23. A method according to claim 22 for the treatment of Fabry disease.
24. A method of effecting gene therapy in a human or animal which method comprises introducing an expression cassette according to any one of claims 1 to 11, a vector according to any one of claims 12 to 14 or a viral strain according to claim 15 into the cells of a human or animal in need of such therapy in an amount resulting in effective expression of a heterologous gene encoding a therapeutic polypeptide in said cells.
25. An expression cassette according to any one of claims 1 to 7 wherein said polynucleotide of interest encodes a polypeptide comprising at least one epitope.
26. An expression cassette according to claim 25 wherein said polypeptide is derived from a pathogenic organism.
27. A vector comprising an expression cassette according to claims 25 or 26.

28. A viral strain comprising an expression cassette according to claim 25 or 26.
29. An expression cassette according to claim 25 or 26, a vector according to claim 27 or a viral strain according to claim 28 for use in a method of vaccinating a bird, fish or mammal.
30. A vaccine comprising an expression cassette according to claim 25 or 26, a vector according to claim 27 or a viral strain according to claim 28 together with a pharmaceutically acceptable carrier or diluent.

ABSTRACT


EUKARYOTIC GENE EXPRESSION CASSETTE AND USES THEREOF

The present invention provides an expression cassette comprising, operably linked, (i) a myosin light chain enhancer, (ii) a promoter selected from a myosin heavy chain promoter and a viral promoter and (iii) a polynucleotide sequence of interest. The expression cassette can be used in methods of medical treatment and vaccination.

THIS PAGE BLANK (USPTO)



A



B




Figure 1: Comparison of constructs pIVGF, pX4F and pMCagalF after transfection of C2C12 myoblasts (see Table 1 for details of constructs). Enzymatic activity of beta-gal and alpha-gal (in Units/mg of protein, left axis) and the normalized alpha-gal activity (in Units alpha-gal/Unit beta-gal, right axis) are shown either 18 hours post-transfection (undifferentiated myoblasts, A) or 10 days post-transfection (fully differentiated myotubes, B). High-Low bars show the results from duplicate experiments.

THIS PAGE BLANK (USPTO)




Figure 2: Comparison of constructs pX3F, pX4F and pX7F after transfection of C2C12 myoblasts (see Table 1 for details of constructs). Enzymatic activity of beta-gal and alpha-gal (in Units/mg of protein, left axis) and the normalized alpha-gal activity (in Units alpha-gal/Unit beta-gal, right axis) 48 hours post-transfection (small myotubes) are shown. High-Low bars show the results from duplicate experiments.

THIS PAGE BLANK (USPTO)




Figure 3: Total alpha-gal enzymatic activity (in Units, 1 Unit=1 nmole/h) of cell extracts and of supernatants from C2C12 myoblasts transfected with three different constructs (Mock=no-DNA transfected) and harvested 48 hours after transfection. Total alpha-gal activity was derived from the original enzymatic activity in cell extracts (in Units/mg) or in supernatants (in Units/L). High-Low bars show the results from duplicate experiments.

THIS PAGE BLANK (USPTO)




Figure 4: Alpha-gal activity in cell extracts from fibroblasts of a Fabry patient that were cultured for 3 days in medium conditioned by C2C12 myoblasts transfected as indicated, either in the absence or in the presence (+M6P) of 5mM mannose-6-phosphate in the culture medium.

Error bars=S.E.M. (n=6).

*Significant difference ($p < 0.01$) with any of the other groups.

THIS PAGE BLANK (USPTO)




Figure 5: Alpha-gal activity in tibialis anterior muscle extracts 7 days after injection. 30 μ g of pX7F DNA in 50 μ l of sterile, endotoxin-free saline (or 50 μ l of saline in control muscles) were injected in tibialis anterior muscles of 5-6 week-old C57Bl/6 mice. Some muscles were pre-injected with myotoxic substances (1.2% BaCl₂ or 0.1M Cardiotoxin from *Naja nigricollis*) 5 days prior to the injection of DNA, in order to induce a cycle of degeneration/regeneration. Error bars=S.E.M. (n=6).

*p < 0.01 between these two groups.

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)